Actively Recruiting
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Led by ImmuneOncia Therapeutics Inc. · Updated on 2026-04-24
62
Participants Needed
3
Research Sites
378 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
CONDITIONS
Official Title
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Adults aged 19 years or older
- Histologically or cytologically confirmed metastatic or locally advanced solid tumors (Part 1)
- For hepatocellular carcinoma cohort: confirmed hepatocellular carcinoma, prior systemic therapy received, lenvatinib-naive, Child Pugh classification A
- For triple negative breast cancer cohort: confirmed triple negative breast cancer, prior systemic regimen received, eligible for paclitaxel or gemcitabine/carboplatin, and no recent use of planned standard chemotherapy unless relapse after 6 months
- For biliary tract cancer cohort: confirmed biliary tract cancer, prior systemic therapy received, lenvatinib-naive
- For B-cell lymphoma cohort: confirmed CD20+ mature B-cell lymphoma, received at least two prior systemic therapies, eligible for rituximab treatment
- At least one measurable tumor lesion by RECIST 1.1
- Availability of tumor tissue for analysis
- ECOG performance status of 0 or 1 and life expectancy of at least 3 months
- Adequate blood, liver, and kidney function
- Prior radiotherapy allowed if completed at least 4 weeks before treatment and disease measurable outside radiotherapy field or progressed post-radiotherapy
- Agreement to use effective contraception
- Willingness and ability to follow study visits, treatment, and testing procedures
You will not qualify if you...
- Use of nonpermitted drugs
- Prior treatment with CD47 or SIRPα targeting agents
- Receiving other anticancer treatments concurrently
- Major surgery or significant injury before screening or planned major surgery during the study
- History of other malignancies besides the current study cancer
- Active infection needing systemic therapy before treatment start
- Active or history of autoimmune disease
- Psychiatric or cognitive conditions that interfere with study participation
- Known severe allergic reactions
- Pregnancy or breastfeeding
- Participation in another clinical trial currently
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
National Cancer Center
Goyang-si, South Korea
Active, Not Recruiting
2
Asan Medical Center, Republic of Korea
Seoul, South Korea
Completed
3
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
S
SUNG YOUNG LEE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here